Jingyi Yan

Jingyi Yan

Auto-generated profile, based on publicly available information

Jingyi Yan

Department of Laboratory Medicine Karolinska Institutet Huddinge Sweden

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
SASofia Appelberg
Sofia Appelberg
GAGustaf Ahlén
Gustaf Ahlén
JYJingyi Yan
Jingyi Yan
NNNegin Nikouyan
Negin Nikouyan
SWSofie Weber
Sofie Weber
MSMatti Sällberg
Matti Sällberg
New variants in the SARS‐CoV‐2 pandemic are more contagious (Alpha/Delta), evade neutralizing antibodies (Beta), or both (Omicron). This poses a challenge in vaccine development according to WHO. We designed a more universal SARS‐CoV‐2 DNA vaccine containing receptor‐binding domain loops from the huCoV‐19/WH01, the Alpha, and the Beta variants, combined with the membrane and nucleoproteins. The vaccine induced spike antibodies crossreactive between huCoV‐19/WH01, Beta, and Delta spike proteins that neutralized huCoV‐19/WH01, Beta, Delta, and Omicron virus in vitro. The vaccine primed nucleoprotein‐specific T cells, unlike spike‐specific T cells, recognized Bat‐CoV sequences. The vaccine protected mice carrying the human ACE2 receptor against lethal infection with the SARS‐CoV‐2 Beta variant. Interestingly, priming of cross‐reactive nucleoprotein‐specific T cells alone was 60% protective, verifying observations from humans that T cells protect against lethal disease. This SARS‐CoV vaccine induces a uniquely broad and functional immunity that adds to currently used vaccines.

13 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JYJingyi Yan
Jingyi Yan
LSLara Sweetapple
Lara Sweetapple
CNChristian An Bính Nordentoft
Christian An Bính Nordentoft
SASofia Appelberg
Sofia Appelberg
SDStéphanie Devignot
Stéphanie Devignot
GAGustaf Ahlén
Gustaf Ahlén
Crimean-Congo hemorrhagic fever virus (CCHFV) is a WHO-priority pathogen with high mortality and wide global distribution. A major challenge in CCHFV vaccine development is identifying antigens that induce functional cellular and humoral immunity. We previously showed that the CCHF nucleoprotein (NP) elicits protective responses in mice and non-human primates but does not induce neutralizing antibodies. We therefore systematically screened six chimeric DNA vaccines expressing different CCHF glycoproteins combined with NP. A construct comprising the ectodomain of the glycoprotein Gc and NP elicited robust antibody and T-cell responses to both antigens. The Gc-NP gene was subsequently developed as a lipid nanoparticle-formulated mRNA vaccine using a scalable manufacturing pipeline. Gc-NP mRNA-LNP induced robust antigen-specific humoral and cellular responses comparable to those elicited by the corresponding DNA vaccine, despite the substantially lower dose. Both vaccine approaches generated Gc-directed neutralizing antibody responses against CCHFV pseudovirus and protected mice against homologous Hoti and heterologous IbAr10200 strain challenge. These findings demonstrate that systematic antigen screening combined with genetic vaccine platforms can identify a potent multi-antigen CCHF vaccine candidate. HIGHLIGHTS: A systematic screening of DNA-based genes identified a highly immunogenic combination of the Gc protein ectodomain and NP. This novel vaccine candidate induced Gc-specific neutralizing antibodies and T-cell responses against both NP and Gc. An mRNA-LNP vaccine expressing the Gc-NP gene further improved immunogenicity and conferred protection against lethal challenge with both CCHFV Hoti and IbAr10200 strains in mice. GRAPHICAL